Edwards’ Transcatheter Valve Product Pipeline
This article was originally published in The Gray Sheet
You may also be interested in...
Research Briefs: Study Updates From Neuronetics, Edwards
Neuronetics starts study enrollment for its NeuroStar transcranial magnetic stimulation to treat postpartum depression. Edwards delays enrollment for Sapien XT Cohort A of the PARTNER II trial. More research news.
First PARTNER II Results Show Progress With Edwards’ TAVR Technology
Next-generation Sapien XT transcatheter aortic valve replacement met its non-inferiority endpoint, and showed some procedural advantages over the FDA-approved Sapien device in the latest data from Edwards Lifescience’s TAVR program, presented at the 2013 American College of Cardiology Scientific Sessions in San Francisco.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.